Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
← catalyst calendarNCT06960395 · readout ≤ 1,108 d
Sponsored by Vir Biotechnology, Inc. (industry) · VIR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
450estimated
Sites
4
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-22 | actual | When the study began enrolling |
| Primary completion | Aug 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor Malignancies
- EGFR Positive Solid Tumors
- EGFR
Interventions
- Drug: VIR-5525 — also filed as AMX-525
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFPrimary Safety Objectives (Parts 1 and 3)
measured From Cycle 1, Day 1 (each cycle is 21 days), up to approximately 52 months.
Primary Safety Objectives (Parts 1 and 3)
measured From Cycle 1, Day 1 (each cycle is 21 days), up to approximately 52 months.
Primary Efficacy Objectives (Parts 2 and 4)
measured From Cycle 1, Day 1 (each cycle is 21 days), up to approximately 52 months.
Permalink · VIR's whole pipeline · Catalyst calendar · Every registered study · What changed